Regulatory Effects of Various IFN-β Formulations Therapy on CXC Chemokines CXCL1 and CXCL9 Gene/Protein Levels in Relapsing-Remitting Multiple Sclerosis Patients Regulatory effects of various IFN-β formulations therapy on CXC chemokines
Iranian Journal of Pharmaceutical Sciences,
Vol. 20 No. 3 (2024),
22 September 2024
https://doi.org/10.22037/ijps.v20i3.45435
Abstract
Multiple sclerosis (MS) is a complex clinical immune system disorder. The most common symptoms of MS are recurrent loss of myelin in conjunction with inflammation in the central nervous system (CNS). Chemokines, as important immune system components, play a role in immune responses. This project aimed to examine and compare the serum levels of CXCL1 and CXCL9 in patients with relapse-remitting MS (RRMS) following therapy with IFN-β formulations. Clinical specimens were collected from 50 unrelated healthy controls, as well as 40 RRMS patients treated with Cinnovex™ (CVX, Interferon beta-1a, made in Iran) and Avonex® (AVX, Interferon beta-1a, made in the USA). The fold changes in gene expression of CXCL1 and CXCL9 compared to the β-actin gene were determined using real-time PCR. The protein expression and serum levels of CXCL1 and CXCL9 were measured using the ELISA method. Data analysis was performed using the ANOVA test. The levels of CXCL1 and CXCL9 significantly increased, with greater upregulation observed with AVX and, to a lesser extent, with CVX. Our study results suggest that AVX is more effective than CVX in regulating the immune system, and the dosage of CVX may need to be increased to achieve a more pronounced therapeutic response in RRMS patients.
- Avonex®
- Cinnovex™
- CXCL1
- CXCL9
- IFN-β Formulations
- Multiple sclerosis
How to Cite
References
Carandini T, Cercignani M, Galimberti D, Scarpini E, Bozzali M. The distinct roles of monoamines in multiple sclerosis: A bridge between the immune and nervous systems? Brain, behavior, and immunity. 2021;94:381-91.
Lünemann JD, Ruck T, Muraro PA, Bar-Or A, Wiendl H. Immune reconstitution therapies: concepts for durable remission in multiple sclerosis. Nature Reviews Neurology. 2020;16(1):56-62.
Martin R, Sospedra M, Eiermann T, Olsson T. Multiple sclerosis: doubling down on MHC. Trends in Genetics. 2021;37(9):784-97.
Giwa AM, Ahmed R, Omidian Z, Majety N, Karakus KE, Omer SM, et al. Current understandings of the pathogenesis of type 1 diabetes: genetics to environment. World journal of diabetes. 2020;11(1):13.
Arneth B. Multiple sclerosis and smoking. The American journal of medicine. 2020;133(7):783-8.
Ghafouri-Fard S, Honarmand K, Taheri M. A comprehensive review on the role of chemokines in the pathogenesis of multiple sclerosis. Metabolic Brain Disease. 2021;36(3):375-406.
Fresegna D, Bullitta S, Musella A, Rizzo FR, De Vito F, Guadalupi L, et al. Re-examining the role of TNF in MS pathogenesis and therapy. Cells. 2020;9(10):2290.
Karimabad MN, Kounis NG, Hassanshahi G, Hassanshahi F, Mplani V, Koniari I, et al. The Involvement of CXC Motif Chemokine Ligand 10 (CXCL10) and Its Related Chemokines in the Pathogenesis of Coronary Artery Disease and in the COVID-19 Vaccination: A Narrative Review. Vaccines. 2021;9(11).
Najmaddini H, Hassanshahi G, Ostadebrahimi H, Barkhordari H, Mashayekhi H, Nazari M, et al. Overproduction of CXC chemokines CXCL1, CXCL9, CXCL10 and CXCL12 in β-thalassemia major or patients. Annals of Saudi medicine. 2014;34(2):122-7.
Zhou C, Gao Y, Ding P, Wu T, Ji G. The role of CXCL family members in different diseases. Cell Death Discovery. 2023;9(1):212.
Karimabad MN, Falahati-Pour SK, Hassanshahi G. Significant role (s) of CXCL12 and the SDF-1 3′ a genetic variant in the pathogenesis of multiple sclerosis. Neuroimmunomodulation. 2016;23(4):197-208.
Radman M, Hassanshahi G, Vazirinejad R, Arababadi MK, Karimabad MN, Khorramdelazad H, et al. Serum levels of the CC chemokines CCL2, CCL5, and CCL11 in food allergic children with different clinical manifestations. Inflammation. 2013;36(3):561-6.
Darakhshan S, Hassanshahi G, Mofidifar Z, Soltani B, Karimabad MN. CXCL9/CXCL10 angiostasis CXC-chemokines in parallel with the CXCL12 as an angiogenesis CXC-chemokine are variously expressed in pre-eclamptic-women and their neonates. Pregnancy hypertension. 2019;17:36-42.
Fatehi F, Mollahosseini M, Hassanshahi G, Khanamani Falahati-Pour S, Khorramdelazad H, Ahmadi Z, et al. CC chemokines CCL2, CCL3, CCL4 and CCL5 are elevated in osteoporosis patients. Journal of biomedical research. 2017;31(5):468-70.
Kortekaas Krohn I, Aerts JL, Breckpot K, Goyvaerts C, Knol E, Van Wijk F, et al. T‐cell subsets in the skin and their role in inflammatory skin disorders. Allergy. 2022;77(3):827-42.
Moghadasi AN. Biosimilars in treatment of multiple sclerosis in Iran. Archives of Iranian Medicine. 2021;24(10):779-82.
Lin LY, Juillard P, Hawke S, Marsh-Wakefield F, Grau GE. Oral Cladribine Impairs Intermediate, but Not Conventional, Monocyte Transmigration in Multiple Sclerosis Patients across a Model Blood-Brain Barrier. International Journal of Molecular Sciences. 2023;24(7):6487.
DiSano KD, Gilli F, Pachner AR. Intrathecally produced CXCL13: A predictive biomarker in multiple sclerosis. Multiple Sclerosis Journal–Experimental, Translational and Clinical.
Holm Hansen R, Højsgaard Chow H, Talbot J, Buhelt S, Nickelsen Hellem MN, Nielsen JE, et al. Peripheral helper T cells in the pathogenesis of multiple sclerosis. Multiple Sclerosis Journal. 2022;28(9):1340-50.
Azin H, Vazirinejad R, Ahmadabadi BN, Khorramdelazad H, Zarandi ER, Arababadi MK, et al. The SDF-1 3'A Genetic Variation of the Chemokine SDF-1alpha (CXCL12) in Parallel with its Increased Circulating Levels is Associated with Susceptibility to MS: A Study on Iranian Multiple Sclerosis Patients. J Mol Neurosci.2011:29.
Hao M, Zhu L, Hou S, Chen S, Li X, Li K, et al. Sensitizing tumors to immune checkpoint blockage via STING agonists delivered by tumor-penetrating neutrophil cytopharmaceuticals. ACS nano. 2023;17(2):1663-80.
La Rosa G, Lonardo MS, Cacciapuoti N, Muscariello E, Guida B, Faraonio R, et al. Dietary Polyphenols, Microbiome, and Multiple Sclerosis: From Molecular Anti-Inflammatory and Neuroprotective Mechanisms to Clinical Evidence. International Journal of Molecular Sciences. 2023;24(8):7247.
Sung PS, Shin E-C. Interferon response in hepatitis C virus-infected hepatocytes: issues to consider in the era of direct-acting antivirals. International Journal of Molecular Sciences. 2020;21(7):2583.
Sariani OK, Eghbalpour S, Kazemi E, Buzhani KR, Zaker F. Pathogenic and therapeutic roles of cytokines in acute myeloid leukemia. Cytokine. 2021;142:155508.
Ng JY, Kishimoto V. Multiple sclerosis clinical practice guidelines provide few complementary and alternative medicine recommendations: a systematic review. Complementary Therapies in Medicine. 2021;56:102595.
Metzemaekers M, Vanheule V, Janssens R, Struyf S, Proost P. Overview of the mechanisms that may contribute to the non-redundant activities of interferon-inducible CXC chemokine receptor 3 ligands. Frontiers in immunology. 2018;8:1970.
Heng AH, Han CW, Abbott C, McColl SR, Comerford I. Chemokine-Driven Migration of Pro-Inflammatory CD4+ T Cells in CNS Autoimmune Disease. Frontiers in Immunology. 2022;13:817473.
Smolders J, Fransen NL, Hsiao C-C, Hamann J, Huitinga I. Perivascular tissue resident memory T cells as therapeutic target in multiple sclerosis. Expert Review of Neurotherapeutics. 2020;20(8):835-48.
Buttmann M, Merzyn C, Rieckmann P. Interferon-beta induces transient systemic IP-10/CXCL10 chemokine release in patients with multiple sclerosis. J Neuroimmunol. 2004;156(1-2):195-203.
Glass CK, Saijo K, Winner B, Marchetto MC, Gage FH. Mechanisms underlying inflammation in neurodegeneration. Cell. 2010;140(6):918-34.
Carrieri PB, Ladogana P, Di Spigna G, de Leva MF, Petracca M, Montella S, et al. Interleukin-10 and interleukin-12 modulation in patients with relapsing-remitting multiple sclerosis on therapy with interferon-beta 1a: differences in responders and non responders. Immunopharmacol Immunotoxicol. 2008;30(4):1-9.
Cohan SL, Hendin BA, Reder AT, Smoot K, Avila R, Mendoza JP, et al. Interferons and multiple sclerosis: Lessons from 25 years of clinical and real-world experience with intramuscular interferon beta-1a (Avonex). CNS drugs. 2021;35:743-67.
Maier S, Simu M, Hutanu A, Barcutean L, Voidazan S, Bajko Z, et al. Clinical Immunological Correlations in Patients with Multiple Sclerosis Treated with Natalizumab. Brain Sciences. 2020;10(11):802.
Faraji F, Hashemi M, Ghiasabadi A, Davoudian S, Talaie A, Ganji A, et al. Combination therapy with interferon beta-1a and sesame oil in multiple sclerosis. Complementary therapies in medicine. 2019;45:275-9.
Nasi M, Bianchini E, De Biasi S, Gibellini L, Neroni A, Mattioli M, et al. Increased plasma levels of mitochondrial DNA and pro-inflammatory cytokines in patients with progressive multiple sclerosis. Journal of Neuroimmunology. 2020;338:577107.
Sorensen TL, Sellebjerg F. Selective suppression of chemokine receptor CXCR3 expression by interferon-beta1a in multiple sclerosis. Mult Scler. 2002;8(2):104-7.
Zhou Y-Q, Liu D-Q, Chen S-P, Sun J, Zhou X-R, Xing C, et al. The role of CXCR3 in neurological diseases. Current Neuropharmacology. 2019;17(2):142-50.
Buttmann M, Merzyn C, Hofstetter HH, Rieckmann P. TRAIL, CXCL10 and CCL2 plasma levels during long-term Interferon-beta treatment of patients with multiple sclerosis correlate with flu-like adverse effects but do not predict therapeutic response. J Neuroimmunol. 2007;190(1-2):170-6.
Dhaiban S, Al-Ani M, Elemam NM, Maghazachi AA. Targeting chemokines and chemokine receptors in multiple sclerosis and experimental autoimmune encephalomyelitis. Journal of Inflammation Research. 2020:619-33.
Krakauer M, Sorensen PS, Khademi M, Olsson T, Sellebjerg F. Dynamic T-lymphocyte chemokine receptor expression induced by interferon-beta therapy in multiple sclerosis. Scand J Immunol.
- Abstract Viewed: 411 times
- IJPS_Volume20_Issue3_ Pages 283- 292 Downloaded: 331 times